National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Lonquex® is indicated for reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Rapid Review

Commenced Completed Outcome
20/08/2013 20/09/2013 Full Pharmacoeconomic Evaluation not recommended